

Docket No.: 102258.170US2

PATENT/OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of

: Attn: Office of Initial
: Patent Examination

Joseph LOSCALZO et al.

Serial No. 10/687,706

: Group Art Unit: 1651

Filed: October 20, 2003

For: METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE
INSUFFICIENCY

Honorable Commissioner for Patents
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Attached is a copy of the Filing Receipt received from the U.S. Patent and Trademark Office in the above-referenced application. The Filing Receipt is missing some of the priority information. Also attached is a copy of the first page of the specification listing the correct priority information. Please add the Priority information as indicated in red on the attached copy of the Filing Receipt. It is requested that a corrected filing receipt be issued.

The domestic priority data on the Official Filing Receipt currently reads:

This application is a CIP of 09/697,317 10/27/2000 PAT 6,635,273
which claims benefit of 60/179,020 01/31/2000
and claims benefit of 60/162,230 10/29/1999

Please correct the domestic priority data on the Official Filing receipt to recite:

**This application is a CIP of 09/697,317 10/27/2000 PAT 6,635,273
which claims benefit of 60/179,020 01/31/2000
and claims benefit of 60/162,230 10/29/1999**


**This application is a continuation of 10/415,136 04/25/2003
which is a 371 of PCT/US01/14245 05/02/2001
which claims benefit of PCT/US00/29528 10/27/2000**

The present application properly claims priority to 6 different applications (2 US nonprovisional applications, 2 PCT applications and 2 provisional US applications). Applicants respectfully request that the Official Filing Receipt be appropriately corrected.

Request for Correct Filing Receipt
US Application No. 10/687,706
Page 2 of 2

Since the error was made by the U.S. Patent and Trademark Office, it is believed that no fee is required with regard to this Request; however, in the event that a fee is required, the Commissioner is authorized to charge such fee to Deposit Account No. 08-0219. A duplicate copy of this letter is attached.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Edward D. Grieff', is written over the typed name and registration number.

Edward D. Grieff
Registration No. 38,898

Date: March 31, 2004

HALE AND DORR LLP
1455 Pennsylvania Avenue, NW
Washington, D.C. 20004
TEL: 202.942.8585
FAX: 202.942.8484




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Page 1 of 2
mym 3/17
MAR 15 2004

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/687,706	10/20/2003	1651	2180	102258.170 US2	3	169	7

25270
EDWARD D GRIEFF
HALE & DORR LLP
1455 PENNSYLVANIA AVE, NW
WASHINGTON, DC 20004



CONFIRMATION NO. 2830

CORRECTED FILING RECEIPT



OC000000012096914

Date Mailed: 03/12/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Joseph Loscalzo, Dover, MA;
Joseph A. Vita, Hingham, MA;
Michael D. Loberg, Boston, MA;
Manuel Worcel, Boston, MA;

Domestic Priority data as claimed by applicant

This application is a CIP of 09/697,317 10/27/2000 PAT 6,635,273
which claims benefit of 60/179,020 01/31/2000
and claims benefit of 60/162,230 10/29/1999

Foreign Applications
This application is a continuation of 10/415,136, 4/25/2003
which is a Section 371 national phase of PCT/US01/14245, 5/2/2001
which claims benefit of PCT/US00/29528, 10/27/2000

If Required, Foreign Filing License Granted: 01/20/2004

Projected Publication Date: 04/29/2004

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

HALE AND DORR LLP Wash, DC

Date: 102258.170 US2

Date: _____

Date: _____

Date: _____

Ext. _____ Dkt'd By VC

Title

Methods of treating vascular diseases characterized by nitric oxide insufficiency

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Methods of Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency Related Applications

This application is (i) a continuation-in-part of U.S. Application No. 09/697,317 filed October 27, 2000, which claims priority to U.S. Application No. 60/179,020 filed January 31, 2000, and U.S. Application No. 60/162,230 filed October 29, 1999; and (ii) a continuation of U.S. Application No. 10/415,136 filed April 25, 2003, which is a § 371 of PCT/US01/14245 filed May 2, 2001, which claims priority to PCT/US00/29528 filed October 27, 2000.

Field of the Invention

The present invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one antioxidant or a pharmaceutically acceptable salt thereof, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one nitrosated angiotensin converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and/or at least one compound used to treat cardiovascular diseases. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The present invention also provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist and/or nitrosated renin inhibitor, and, optionally, at least one antioxidant and/or at least one compound used to treat cardiovascular diseases. The present invention also provides methods of treating and/or preventing Raynaud's syndrome by administering a therapeutically effective amount of at least one antioxidant or a pharmaceutically acceptable salt thereof, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one nitrosated angiotensin-